Latham & Watkins represented the underwriters in the offering.Pyxis Oncology, Inc., a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
